Previous Close | 4.1500 |
Open | 4.1400 |
Bid | 0.0000 x 1200 |
Ask | 0.0000 x 800 |
Day's Range | 4.1300 - 4.1700 |
52 Week Range | 3.3900 - 8.7500 |
Volume | |
Avg. Volume | 103,177 |
Market Cap | 459.453M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -11.0410 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for PRE
Prenetics Group Limited (Nasdaq: PRE), a global leader in genomic and diagnostic testing, has introduced a novel, non-invasive, at-home screening test – ColoClear by Circle (ColoClear), for detecting early signs of colorectal cancer. Colorectal cancer is the second most common cancer in Hong Kong, accounting for 15.8% of total new cancers in 2019[1]. Combining advanced stool DNA technology with a faecal immunochemical test (FIT), the revolutionary test is the first line of defense against one of
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the first quarter ended March 31, 2022. The Company recorded strong operational and financial performance driven by solid diagnostics and genetic testing demand, and is on track to achieve revenue guidance for FY2022.
IPO Edge and the Palm Beach Hedge Fund Association hosted a fireside chat with the CEO & Co-Founder of Prenetics Limited and the CEO & Director of Artisan Acquisition […]